Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

What is the biology behind immunotherapy for MM?

Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA
What is the biology behind immunotherapy for MM? ( Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA )
3 Mar 2017

Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma

Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma ( Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA )
3 Mar 2017

Is precision myeloma medicine more hype than reality?

Dr Suzanne Lentzsch - Columbia University, New York, USA
Is precision myeloma medicine more hype than reality? ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017

Asia-Pacific approaches to myeloma trials

Prof Chng Wee Joo - National University Health System, Singapore, Singapore
Asia-Pacific approaches to myeloma trials ( Prof Chng Wee Joo - National University Health System, Singapore, Singapore )
3 Mar 2017

Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
3 Mar 2017

Bone disease and management of myeloma complications

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Bone disease and management of myeloma complications ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
3 Mar 2017

Monoclonal antibodies in multiple myeloma

Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
Monoclonal antibodies in multiple myeloma ( Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain )
2 Mar 2017

Promising myeloma agents in phase II trials

Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA
Promising myeloma agents in phase II trials ( Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA )
2 Mar 2017

Ongoing transplant phase III trials for myeloma

Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
Ongoing transplant phase III trials for myeloma ( Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA )
2 Mar 2017

Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update

Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update ( Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA )
2 Mar 2017

Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma

Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )
2 Mar 2017

Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma

Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )
2 Mar 2017